SYRE · Spyre Therapeutics Inc
Price
Snapshot
50 fields · last close| Market Cap | $8.87B |
| P/E | — |
| Float | — |
| Beta | 2.95 |
| Volatility | 73.8% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Mid cap |
| Macro sensitivity | Very High |
| Clavix score | — |
| Price | 78.63 |
| Change | +0.00% |
| Prev Close | 78.63 |
| Open | 100.56 |
| Day Low | 98.79 |
| Day High | 103.57 |
| Avg Vol | 1 |
| Avg $ Vol | $115.8M |
| 52W High | 108.92 |
| 52W Low | 14.51 |
| 52W Pos | 67.9% |
| From High | −27.81% |
| From Low | +442.09% |
| Max DD 1Y | −14.06% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −23.86% |
| SMA 50 | −20.10% |
| SMA 200 | +30.99% |
| RSI (14) | 38.9 |
| Vol 30D | 63.3% |
| Vol 90D | 66.9% |
| 1Y Range | 15–109 |
| Daily bars | 501 |
| Perf Week | −13.15% |
| Perf Month | −4.35% |
| Perf Quarter | +29.82% |
| Perf Half Y | +116.95% |
| Perf Year | +448.74% |
| Perf YTD | +157.13% |
| Prev Day | +0.00% |
| Clavix | — |
| Debt / Eq | 0.00 |
| Curr Ratio | 13.25 |
| Int Cover | -2.1× |
| FCF Margin | — |
| Rev Growth | — |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | — |
Recent news
most recent scored articles · the chip is the article’s score · click to openMizuho raised its price target on Spyre Therapeutics (NASDAQ:SYRE) from $84.00 to $120.00 and issued an 'outperform' rating in a research note on Monday.
The article frames Spyre Therapeutics' stock outlook as dependent on upcoming 2026 study catalysts, with the investment thesis hinging on whether its broad IBD pipeline can deliver meaningful clinical proof-of-concept data. The article body provides limited additional detail beyond this thesis statement.
Spyre Therapeutics director Michael Thomas Henderson sold 20,000 shares of company stock at an average price of $100.00 per share on June 22nd, for a total transaction value of $2,000,000, leaving him with 68,606 shares.
Spyre Therapeutics reported positive ulcerative colitis data for two of its IBD candidates, SPY-001 and SPY-002, drawing positive analyst reactions.
Spyre Therapeutics (SYRE) has completed enrollment in all sub-studies of its Phase II SKYWAY basket trial evaluating SPY072 across three rheumatic diseases, sending shares higher.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| PTGX | Protagonist Therapeutics Inc | B | $8.82B | 106.80 | 1.19 | Compare |
| CYTK | Cytokinetics Inc | B+ | $8.82B | — | 0.41 | Compare |
| CAI | Caris Life Sciences Inc | C | $8.55B | 79.37 | 0.40 | Compare |
| TGTX | TG Therapeutics Inc | B- | $8.32B | 18.84 | 1.82 | Compare |
| ARWR | Arrowhead Pharmaceuticals Inc | C+ | $8.25B | — | 1.33 | Compare |
| TWST | Twist Bioscience Corp | D+ | $9.75B | — | 2.15 | Compare |
| KRYS | Krystal Biotech Inc | B | $9.79B | 40.23 | 0.64 | Compare |
| MDGL | Madrigal Pharmaceuticals Inc | B | $10.63B | — | -1.10 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.